Demir Melike, Cizmecioglu Onur
Department of Molecular Biology and Genetics, Bilkent University, Ankara, Turkey.
Cancer Diagn Progn. 2022 May 3;2(3):391-404. doi: 10.21873/cdp.10122. eCollection 2022 May-Jun.
BACKGROUND/AIM: Tyrosine kinases have crucial functions in cell signaling and proliferation. The phosphatidylinositol 3-kinase (PI3K) pathway is frequently deregulated in human cancer and is an essential regulator of cellular proliferation. We aimed to determine which tyrosine kinases contribute to resistance elicited by PI3K silencing and inhibition.
To mimic catalytic inactivation of p110α/β, specific p110α (BYL719) and p110β (KIN193) inhibitors were used in addition to genetic knock-out in in vitro assays. Cell viability was assessed using crystal violet staining, whereas cellular transformation ability was analyzed by soft-agar growth assays.
Activated zeta chain of T-cell receptor-associated protein kinase 70 (ZAP70) generated resistance to PI3K inhibition. This resistance was via activation of the Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3) axis. We demonstrated that activated ZAP70 has a high transforming capability associated with the formation of malignant phenotype in untransformed cells and has the potential to be a tumor-initiating factor in cancer cells.
ZAP70 may be a potent driver of proliferation and transformation in untransformed cells and is implicated in resistance to PI3K inhibitors in cancer cells.
背景/目的:酪氨酸激酶在细胞信号传导和增殖中发挥着关键作用。磷脂酰肌醇3-激酶(PI3K)通路在人类癌症中经常失调,是细胞增殖的重要调节因子。我们旨在确定哪些酪氨酸激酶会导致PI3K沉默和抑制所引发的耐药性。
为模拟p110α/β的催化失活,除了在体外实验中进行基因敲除外,还使用了特异性的p110α(BYL719)和p110β(KIN193)抑制剂。使用结晶紫染色评估细胞活力,通过软琼脂生长实验分析细胞转化能力。
T细胞受体相关蛋白激酶70(ZAP70)的活化ζ链产生了对PI3K抑制的耐药性。这种耐药性是通过激活Janus激酶/信号转导和转录激活因子3(JAK/STAT3)轴实现的。我们证明,活化的ZAP70具有高转化能力,与未转化细胞中恶性表型的形成有关,并且有可能成为癌细胞中的肿瘤起始因子。
ZAP70可能是未转化细胞增殖和转化的有效驱动因子,并与癌细胞对PI3K抑制剂的耐药性有关。